Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Viatris Inc.

NASDAQ

Market Cap.

12.39B

Avg. Volume

8.86M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Viatris Inc.!

Still processing it, give me a bit more time...

Viatris Inc. News

Viatris Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - Specialty & Generic
viatris.com

About Viatris Inc.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc. Earnings & Revenue

Viatris Inc. Financials

Table Compare

Compare VTRS metrics with:

   

Earnings & Growth

VTRS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

VTRS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

VTRS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

VTRS

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Viatris Inc. Income

Viatris Inc. Balance Sheet

Viatris Inc. Cash Flow

Viatris Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityNeutral
Return on AssetsBuy
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Buy
Price/Book RatioSell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Viatris Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

0.4800

Payment DateDividendFrequency
2024-06-140.12Quarterly
2024-03-180.12Quarterly
2023-12-150.12Quarterly
2023-09-150.12Quarterly
2023-06-160.12Quarterly

Historical Market Cap

Shares Outstanding

Viatris Inc. Executives

NameRole
Mr. Scott Andrew SmithChief Executive Officer & Director
Mr. Brian S. RomanChief Legal Officer
Mr. Ramkumar V. RayapureddyChief Information Officer
Dr. Jeffrey Nau MMS, Ph.D.President of Viatris Eye Care Division
Mr. Paul B. CampbellChief Accounting Officer, Senior Vice President & Corporate Controller
NameRoleGenderDate of BirthPay
Mr. Scott Andrew SmithChief Executive Officer & DirectorMale19625.07M
Mr. Brian S. RomanChief Legal OfficerMale19712.51M
Mr. Ramkumar V. RayapureddyChief Information OfficerMale

--

Dr. Jeffrey Nau MMS, Ph.D.President of Viatris Eye Care Division1976

--

Mr. Paul B. CampbellChief Accounting Officer, Senior Vice President & Corporate ControllerMale1968

--

Viatris Inc. Insider Trades

Date18 Apr
NameLe Goff Corinne
RoleChief Commercial Officer
TransactionAcquired
TypeA-Award
Shares78688
Date18 Apr
NameLe Goff Corinne
RoleChief Commercial Officer
TransactionAcquired
TypeA-Award
Shares110162
Date15 Apr
NameLe Goff Corinne
Role
TransactionDisposed
Type
Shares0
Date2 Apr
NameMalik Rajiv
RoleDirector
TransactionAcquired
TypeA-Award
Shares18845
Date13 Mar
NameMauro Anthony
RoleSee Remarks
TransactionDisposed
TypeS-Sale
Shares250000
DateNameRoleTransactionTypeShares
18 AprLe Goff CorinneChief Commercial OfficerAcquiredA-Award78688
18 AprLe Goff CorinneChief Commercial OfficerAcquiredA-Award110162
15 AprLe Goff CorinneDisposed0
2 AprMalik RajivDirectorAcquiredA-Award18845
13 MarMauro AnthonySee RemarksDisposedS-Sale250000

Discover More

Streamlined Academy

Viatris Inc.

NASDAQ

Market Cap.

12.39B

Avg. Volume

8.86M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Viatris Inc. News

Viatris Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Viatris Inc. Earnings & Revenue

Viatris Inc. Income

Viatris Inc. Balance Sheet

Viatris Inc. Cash Flow

Viatris Inc. Financials Over Time

Viatris Inc. Executives

NameRole
Mr. Scott Andrew SmithChief Executive Officer & Director
Mr. Brian S. RomanChief Legal Officer
Mr. Ramkumar V. RayapureddyChief Information Officer
Dr. Jeffrey Nau MMS, Ph.D.President of Viatris Eye Care Division
Mr. Paul B. CampbellChief Accounting Officer, Senior Vice President & Corporate Controller
NameRoleGenderDate of BirthPay
Mr. Scott Andrew SmithChief Executive Officer & DirectorMale19625.07M
Mr. Brian S. RomanChief Legal OfficerMale19712.51M
Mr. Ramkumar V. RayapureddyChief Information OfficerMale

--

Dr. Jeffrey Nau MMS, Ph.D.President of Viatris Eye Care Division1976

--

Mr. Paul B. CampbellChief Accounting Officer, Senior Vice President & Corporate ControllerMale1968

--

Viatris Inc. Insider Trades

Date18 Apr
NameLe Goff Corinne
RoleChief Commercial Officer
TransactionAcquired
TypeA-Award
Shares78688
Date18 Apr
NameLe Goff Corinne
RoleChief Commercial Officer
TransactionAcquired
TypeA-Award
Shares110162
Date15 Apr
NameLe Goff Corinne
Role
TransactionDisposed
Type
Shares0
Date2 Apr
NameMalik Rajiv
RoleDirector
TransactionAcquired
TypeA-Award
Shares18845
Date13 Mar
NameMauro Anthony
RoleSee Remarks
TransactionDisposed
TypeS-Sale
Shares250000
DateNameRoleTransactionTypeShares
18 AprLe Goff CorinneChief Commercial OfficerAcquiredA-Award78688
18 AprLe Goff CorinneChief Commercial OfficerAcquiredA-Award110162
15 AprLe Goff CorinneDisposed0
2 AprMalik RajivDirectorAcquiredA-Award18845
13 MarMauro AnthonySee RemarksDisposedS-Sale250000

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - Specialty & Generic
viatris.com

About Viatris Inc.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Viatris Inc.!

Still processing it, give me a bit more time...

Viatris Inc. Financials

Table Compare

Compare VTRS metrics with:

   

Earnings & Growth

VTRS

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

VTRS

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

VTRS

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

VTRS

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Viatris Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

0.4800

Payment DateDividendFrequency
2024-06-140.12Quarterly
2024-03-180.12Quarterly
2023-12-150.12Quarterly
2023-09-150.12Quarterly
2023-06-160.12Quarterly

Viatris Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityNeutral
Return on AssetsBuy
Debt/Equity RatioStrong Buy
Price/Earnings RatioStrong Buy
Price/Book RatioSell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More